Valuation: BELLUS Health

Market Cap 1.86B 1.64B 1.51B 1.41B 2.65B 176B 2.7B 18.12B 7.01B 86.94B 7B 6.85B 301B P/E 2021
-8.95x
P/E 2022 -12.4x
Enterprise Value 1.53B 1.34B 1.24B 1.16B 2.17B 144B 2.21B 14.85B 5.75B 71.29B 5.74B 5.62B 247B EV / Sales 2021
36,416x
EV / Sales 2022 43,771x
Free-Float
81.52%
Yield 2021 *
-
Yield 2022 -
3 years 19.24
Extreme 19.24
19.75
5 years 3.32
Extreme 3.32
19.9
10 years 0.76
Extreme 0.756
19.9
Manager TitleAgeSince
President - 2023-05-31
Director of Finance/CFO 53 2020-12-06
Chief Tech/Sci/R&D Officer 69 2009-12-31
Director TitleAgeSince
Chairman 79 2001-12-31
Director/Board Member 54 2009-05-31
Director/Board Member 80 2009-05-31
Date Insider Type Main position Quantity % Market Cap.
23-06-28OtherCompany 0 0%
23-06-21Option

Executive/Senior Manager

75,000 0.0593%
23-06-21Option

Director

21,546 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%-.--%-.--%+0.72% 1.87B
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +0.09%+4.33%+38.03%+114.64% 22.82B
Weighted average by Cap. +0.26%+5.09%+48.10%+119.14%

Financials

2021 2022
Net sales 16K 14.03K 12.93K 12.11K 22.7K 1.51M 23.17K 155K 60.14K 746K 60.08K 58.77K 2.59M 16K 14.03K 12.93K 12.11K 22.7K 1.51M 23.17K 155K 60.14K 746K 60.08K 58.77K 2.59M
Net income -71.22M -62.45M -57.56M -53.89M -101M -6.72B -103M -692M -268M -3.32B -267M -262M -11.51B -76.08M -66.71M -61.49M -57.57M -108M -7.18B -110M -739M -286M -3.55B -286M -279M -12.3B
Net Debt -248M -217M -200M -188M -352M -23.39B -359M -2.41B -932M -11.56B -931M -911M -40.08B -336M -294M -271M -254M -476M -31.67B -486M -3.26B -1.26B -15.65B -1.26B -1.23B -54.28B
Logo BELLUS Health
BELLUS Health Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant is a highly selective antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. It is being evaluated in the CALM phase III clinical development programmed. It is developing camlipixant for the treatment of adults with RCC. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.
Employees
74